Nonalcoholic fatty liver disease;Niealkoholowa choroba stłuszczeniowa wa̧troby

Gastroenterologia Polska

Volumn 11, Issue 3, 2004, Pages 271-278

  Tacikowski, Tadeusz ^a   Dzieniszewski, Jan ^a   Ciok, Janusz ^a   Godziemba Maliszewska, Ewa ^a  

^a Klin Chorob Metab/Gastroenterol   (Poland)

Author keywords

Fatty liver; NAFLD; NASH; Nonalcoholic fatty liver disease

Indexed keywords

ANEMIA; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; ECHOGRAPHY; EPIDEMIOLOGICAL DATA; HISTOPATHOLOGY; HUMAN; HYPERLIPOPROTEINEMIA; INSULIN RESISTANCE; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; REVIEW; RISK FACTOR;

EID: 3042601396     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Alba L.M., Lindor K.: Review article: non-alcoholic fatty lver disease. Aliment, Pharmacol. Ther., 2003, 17, 977-987.
2. Ludwig J., Viggano T., McGill D.B., Ott B.J.: Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc., 1980, 55, 434-438.
3. Allard J.P.: Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract. Res. Clin. Gastroenterol., 2002, 16, 783-795.
4. Schaffner F.: Nonalcoholic fatty liver disease. [w]: Progress in liver disease, (red.) F. Schaffner. Grune Stratton 1986, 283.
5. Sherlock S., Dooley J.: Nutritional and Metabolic Liver Diseases. [w] Diseases of the liver and biliary system, (red.) S. Sherlock, J. Dooley. Blackwell Publishing, Oxford 2002, 426.
6. Clark J.M., Brancati F.L., Diehl A.M.E.: Nonalcoholic fatty liver diseases; the most common cause of abnormal liver enzymes in the U.S. population. Gastroenterology, 2001, 120, A-65.
7. Angulo P.: Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
8. Luyckx F.H., Desaive C., Thiry A., Dewe W., Scheen A.J., Gielen J.E., Lefebvre P.J.: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord., 1998, 22, 222-226.
9. Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., Wiedmeyer H.M., Byrd-Holt D.D.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and nutrition Examination Survey, 1988-1994. Diabetes Care, 1998, 21, 518-524.
10. Program Pol-Monica. Warszawa: Kompleksowa ocena stanu zdrowia ludnoṡci Warszawy w roku 1993 i jego zmian w latach 1984-1993, (red.) S. Rywik. Czȩść V. Instytut Kardiologii, Warszawa 1995.
11. Tacikowski T., Milewski B., Dzieniszewski J., Rakoczy A., Klosiewicz-Latoszek L.: Stłuszczenie wa̧troby oceniane badaniem ultrasonograficznym u osób z hiperlipoproteinemia̧. Wiad. Lek., 1994, 47, 726-730.
12. Matsuura K., Tobe K., Tsuji T.: Fatty liver and obesity in university students. Nippon Shokakibyo Gakkai Zasshi, 1995, 92, 1743-1751.
13. Osono Y., Nakajiama K., Hata Y.: Hypertriglyceridemia and fatty liver: clinical diagnosis of fatty liver and lipoprotein profiles in hypertriglyceridemic patients with fatty liver. J. Atheroscler. Thromb., 1995, 2, supl. S47.
14. Lu S.N., Wang L.Y., Chang W.Y., Chen C.J., Su W.P., Chen S.C., Chuang W.L., Hsieh M.Y.: Abdominal sonographic screening in a single community. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih, 1990, 6, 643-646.
15. Reaven G.M.: Role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-1607.
16. Kral J.G., Schaffner F., Pierson R.N. Jr, Wang J.: Body fat topography as an independent predictor of fatty liver. Metabolism, 1993, 42, 548-551.
17. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., Clore J.N.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-1192.
18. Boden G.: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 1997, 46, 3-10.
19. Fan C.Y., Pan J., Usuda N., Yeldandi A.V., Rao M.S., Reddy J.K.: Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem., 1998, 19, 273, 15639-15645.
20. Caldwell S.H., Swerdlow R.H., Khan E.M., Iezzoni J.C., Hespenheide E.E., Parks J.K., Parker W.D. Jr: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol., 1999, 31, 430-434.
21. Cortez-Pinto H., Chatham J., Chacko V.P., Arnold C., Rashid A., Diehl A.M.: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA, 1999, 282, 1659-1664.
22. Day C.P., James O.F.: Steatohepatitis: a tale of two "hits"? Gastroenterology, 1998, 114, 842-845.
23. Leclercq I.A., Farrell G.C., Schriemer R., Robertson G.R.: Leptin is essential for the hepatic fibrogenic response to chronic liver injury. Hepatology, 2002, 37, 206-213.
24. Boden G.: Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5, 545-549.
25. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M.: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science, 1996, 271, 665-668.
26. Tacikowski T., Milewski B., Dzieniszewski J., Walewska-Zielecka B.: Stłuszczenie wa̧troby oceniane badaniem histopatologicznym u osób z hiperlipoproteinemia̧. Wiad. Lek., 1994, 47, 731-737.
27. Tacikowski T., Dzieniszewski J.: Prevalence of Non-Alcoholic Hepatic Steatosis Depending on Overweight Degree in Individuals with Hyperlipoproteinaemia. Adv. Clin. Exp. Med., 2001, 10, 139-143.
28. Liu T.Y., Lu S.N., Su W.P., Chang W.Y., Wang L.Y., Hsieh M.Y., Chang W.L., Chen S.C., Chen C.J.: Prediction of fatty liver from serum triglyceride levels and body weight indexes. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih, 1990, 6, 289-294.
29. Tacikowski T., Dzieniszewski J., Rakoczy A., Tacikowska M.: Hipertrójglicerydemia jako niezależny od otyłości czynnik ryzyka rozwoju stłuszczenia wa̧troby u osób z hiperlipoproteinemia̧. Gastroenterol. Pol., 2001, 8, 143-147.
30. Assy N., Kaita K., Mymin D., Levy C., Rosser B., Minuk G.: Fatty infiltration of liver in hyperlipidemic patients. Dig. Dis. Sci., 2000, 45, 1929-1934.
31. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., Melchionda N.: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
32. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., Cassader M., David E., Cavallo-Perin P., Rizzetto M.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology, 2002, 35, 367-372.
33. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., Karim R., Lin R., Samarasinghe D., Liddle C., Weltman M., George J.: NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35, 373-379.
34. Diehl A.M.: Nonalcoholic steatohepatitis. Semin. Liver Dis., 1999, 19, 221-229.
35. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., Jazwinska E.C., Powell L.W.: Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 1998, 114, 311-318.
36. MacDonald G.A., Ward P.J., George D.K.: Iron and fibrosis in nonalcoholic fatty liver disease. Hepatology, 2000, 31, 549.
37. Ratziu V., Giral P., Charlotte F., Bruckert E., Thibault V., Theodorou I., Khalil L., Turpin G., Opolon P., Poynard T.: Liver fibrosis in overweight patients. Gastroenterology, 2000, 118, 1117-1123.
38. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., Le Gall J.Y., Brissot P., David V., Deugnier Y.: Insulin resistance-associated hepatic iron overload. Gastroenterology, 1999, 117, 1155-1163.
39. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., McCullough A.J.: Hepatic iron and nonalcoholic fatty liver disease. Hepatology, 1999, 30, 847-850.
40. Doherty J.F., Adam E.J., Griffin G.E., Golden M.H.: Ultrasonographic assessment of the extent of hepatic steatosis in severe malnutrition. Arch. Dis. Child., 1992, 67, 1348-1352.
41. Suzuki K., Hayashi N., Sasaki Y., Kono M., Kasahara A., Imai Y., Fusamoto H., Kamada T.: Evaluation of structural change in diffuse liver disease with frequency domain analysis of ultrasound, Hepatology, 1993, 17, 1041-1046.
42. Yamasaki H., Tanemura M., Morimoto Y., Hashimoto J., Sakamoto T., Yamasaki Y., Kuwata K.: Study of postgastrectomy fatty liver. Nippon Geka Gakkai Zasshi, 1992, 93, 1384-1389.
43. Pamilo M., Sotaniemi E.A., Suramo I., Lahde S., Arranto A.J.: Evaluation of liver steatotic and fibrous content by computerized tomography and ultrasound. Scand. J. Gastroenterol, 1983, 18, 743-747.
44. Bydder G.M., Chapman R.W., Harry D., Bassan L., Sherlock S., Kreel L.: Computed tomography attenuation values in fatty liver. J. Comput. Tomogr., 1981, 5, 33-35.
45. Ricci C., Longo R., Gioulis E., Bosco M., Pollesello P., Masutti F., Croce L.S., Paoletti S., de Bernard B., Tiribelli C., Dalla Palma L.: Noninvasive in vivo quantitative assessment of fat content in human liver. J. Hepatol., 1997, 27, 108-113.
46. Schmitt W.G., Hubener K. H.: Attenuation values of normal and pathological liver tissue as a basis for computer tomographic densitometry of fatty livers. Rofo Fortschr. Geb. Rontgenstr. Nuklear-med., 1978, 129, 555-559.
47. Ducommun J.C., Goldberg H.I., Korobkin M., Moss A.A., Kressel H.Y.: The relation of liver fat to computed tomography numbers: a preliminary experimental study in rabbits. Radiology, 1979, 130, 511-513.
48. Piekarski J., Goldberg H.I., Royal S.A., Axel L., Moss A.A.: Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology, 1980, 137, 727-729.
49. Goldberg H.I.: Diffuse disease of the liver. [w]: Radiology Diagnosis - Imaging - Intervention, (red.) J.M. Tavera. J.B. Lippincott Company, Philadelphia 1994, t. IV, rozdz. 62, 1-11.
50. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., Mullen K.D., Cooper J.N., Sheridan M.J.: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 745-750.
51. Banner B.F., Savas L., Zivny J., Tortorelli K., Bonkovsky H.L.: Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. Am. J. Clin. Pathol., 2000, 114, 860-866.
52. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R.: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol., 1999, 94, 2467-2474.
53. Evans C.D., Oien K.A., McSween R.N., Mills P.R.: Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J. Clin. Pathol., 2002, 55, 689-692.
54. Dixon J.B., Bhathal P.S., O'Brien P.E.: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology, 2001, 121, 91-100.
55. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., Cristanini G., Tiribelli C.: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med., 2000, 18, 112-117.
56. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S.: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.
57. Andersen T., Gluud C., Franzmann M.B., Christoffersen R.: Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol., 1991, 12, 224-229.
58. Basaranoglu M., Acbay O., Sonsuz A.: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol., 1999, 31, 384.
59. Lavine J. E.: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr., 2000, 136, 734-738.
60. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N.: Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, 893-894.
61. Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., Rakela J., McGill D.B.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology, 1996, 23, 1464-1467.
62. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., Sheppard B.L.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2001, 96, 519-525.
63. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., Desimone C., Song X.Y., Diehl A.M.: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003, 37, 343-350.
64. Contos M.J., Cales W., Sterling R.K., Luketic V.A., Shiffman M.L., Mills A.S., Fisher R.A., Ham J., Sanyal A.J.: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl., 2001, 7, 363-733.
65. Charlton M., Kasparova P., Weston S., Lindor K., Maor-Kendler Y., Wiesner R.H., Rosen C.B., Batts K.P.: Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl., 2001, 7, 608-614.
66. Neuschwander-Tetri B.A., Caldwell S.H.: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 2003, 37, 1202-1219.
67. Laurin J.: Motion - All patients with NASH need to have a liver biopsy: Arguments against the motion. Can. J. Gastroenterol., 2002, 16, 722-726.
68. Talwalkar J.A.: Motion - All patients with NASH need to have a liver biopsy: Arguments for the motion. Can. J. Gastroenterol., 2002, 16, 718-722.
69. Younossi Z.M., Diehl A.M., Ong J.P.: Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology, 2002, 35, 746-752.